Embolic Protection with the TriGuard 3 System in Nonagenarian Patients Undergoing Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis.
Alexander LindRolf Alexander JánosiMatthias TotzeckArjang RuhparwarTienush RassafFadi Al-RashidPublished in: Journal of clinical medicine (2022)
Age alone is no longer a contraindication for TAVR. CEPD using the Triguard 3 system in nonagenarian TAVR patients was feasible and safe and did not increase access site complications.
Keyphrases
- aortic stenosis
- transcatheter aortic valve replacement
- ejection fraction
- aortic valve
- aortic valve replacement
- transcatheter aortic valve implantation
- patients undergoing
- left ventricular
- end stage renal disease
- coronary artery disease
- newly diagnosed
- chronic kidney disease
- risk factors
- peritoneal dialysis
- heart failure
- patient reported outcomes
- patient reported